Related Experiment Videos
Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside
1Health Sciences Center, Sunnybrook and Women's College, Department of Pathology, University of Toronto, Canada.
Abstract:
Molecular alterations in breast cancer are being incorporated into the development of new treatment strategies. The HER-2/neu oncogene has been extensively investigated as a prognostic factor and recently as a predictor of response to chemotherapy or endocrine therapy. The development of a humanized anti-HER-2 monoclonal antibody (Herceptin) and the encouraging results obtained in the treatment of patients with HER-2 overexpressing metastatic breast cancer with this antibody have resulted in renewed interest in HER-2/neu. This article reviews the current knowledge of HER-2/neu both as a prognostic and a predictive factor. Problems associated with the standardization of the methodology for assessing HER-2/neu status and clinically significant cut-off points are addressed.
Insights
The HER-2/neu oncogene is crucial for breast cancer treatment strategies. Understanding its role as a prognostic and predictive factor, alongside standardized assessment methods, is vital for effective therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Molecular alterations guide breast cancer treatment development.
- The HER-2/neu oncogene is a key focus, studied for its prognostic and predictive roles.
- The anti-HER-2 antibody Herceptin has shown promise in HER-2-overexpressing metastatic breast cancer.
Purpose of the Study:
- To review current knowledge on HER-2/neu as a prognostic and predictive factor in breast cancer.
- To discuss challenges in standardizing HER-2/neu assessment methodologies.
- To address the definition of clinically significant cut-off points for HER-2/neu status.
Main Methods:
- Literature review of studies investigating HER-2/neu in breast cancer.
- Analysis of prognostic and predictive data related to HER-2/neu.
- Examination of methodologies for HER-2/neu status assessment.
Main Results:
- HER-2/neu status is integral to treatment decisions for breast cancer patients.
- Standardization issues in HER-2/neu testing impact clinical interpretation.
- Defining precise cut-off points remains a challenge for accurate patient stratification.
Conclusions:
- HER-2/neu is a significant factor in breast cancer prognosis and predicting treatment response.
- Standardized HER-2/neu assessment is critical for reliable clinical application.
- Further research is needed to refine HER-2/neu testing and establish definitive clinical cut-offs.